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Abstract
Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) is the major mediator of the angiogenic effects of VEGF. In addition
to its well known role as a membrane receptor that activates multiple signaling pathways, VEGFR2 also has a nuclear
localization. However, what VEGFR2 does in the nucleus is still unknown. In the present report we show that, in endothelial
cells, nuclear VEGFR2 interacts with several nuclear proteins, including the Sp1, a transcription factor that has been
implicated in the regulation of genes needed for angiogenesis. By in vivo chromatin immunoprecipitation (ChIP) assays, we
found that VEGFR2 binds to the Sp1-responsive region of the VEGFR2 proximal promoter. These results were confirmed by
EMSA assays, using the same region of the VEGFR2 promoter. Importantly, we show that the VEGFR2 DNA binding is directly
linked to the transcriptional activation of the VEGFR2 promoter. By reporter assays, we found that the region between -300/-
116 relative to the transcription start site is essential to confer VEGFR2-dependent transcriptional activity. It was previously
described that nuclear translocation of the VEGFR2 is dependent on its activation by VEGF. In agreement, we observed that
the binding of VEGFR2 to DNA requires VEGF activation, being blocked by Bevacizumab and Sunitinib, two anti-angiogenic
agents that inhibit VEGFR2 activation. Our findings demonstrate a new mechanism by which VEGFR2 activates its own
promoter that could be involved in amplifying the angiogenic response.
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Introduction
Angiogenesis is the formation of new blood vessels from a pre-
existing vascular net. This process is essential during embryonic
development and for normal homeostasis of adult tissues. In
addition, angiogenesis was recognized to be fundamental in the
progression of many pathological diseases such as cancer because
it is an essential event in tumor growth and metastatic
dissemination [1].
Angiogenesis is a complex dynamic process regulated by a
balance between pro-angiogenic and anti-angiogenic factors.
Vascular Endothelial Growth Factor (VEGF) is one of the most
important pro-angiogenic factors. VEGF stimulates angiogenesis
by binding to the VEGF receptor (VEGFR)-1 and VEGFR2
receptor tyrosine kinases (RTKs) on the cell surface of endothelial
cells (EC) [2]. Both VEGFR1 and VEGFR2 have seven Ig-like-
domains in the extracellular domain, a single transmembrane
region and a split tyrosine kinase intracellular domain [2].
VEGFR2 is considered to be the major mediator of several
physiological and pathological effects of VEGF on EC. These
include proliferation, survival, migration and permeability [2].
VEGF binds to the extracellular domain of VEGFR2 inducing
receptor dimerization and autophosphorylation of specific intra-
cellular tyrosine residues leading to the activation of different
signaling pathways [2].
Recognition of the VEGF pathway as a key regulator of
angiogenesis has led to the development of several VEGF-targeted
agents demonstrating therapeutic efficacy in several human
cancers [3]. Therefore, several approaches have been developed
to inhibit VEGF signaling, including neutralization of the ligand
or receptor by antibodies, and blocking VEGF receptor activation
and signaling with tyrosine kinase inhibitors [4]. The pioneers of
the clinical proof-of-concept for angiogenesis inhibitors are
Bevacizumab (AvastinH, Genentech/Roche), a ligand-trapping
monoclonal antibody [5], and Sunitinib (SutentH, Pfizer), which
targets receptor tyrosine kinases [6], principally VEGFR2. Their
goal is to block the VEGF signaling mediated by the plasma
membrane receptor VEGFR2.
Besides the membrane localization of VEGFR2, it was
demonstrated that it could also be found in the cell nucleus. In
contrast to VEGFR1, we found that VEGFR2 translocates to the
nucleus upon VEGF stimulation in a process that required
phosphorylation of the receptor [7]. Furthermore, we demon-
strated that in vitro wounding of ECs monolayers leads to a rapid
and transient internalization of VEGF and VEGFR2 to the
nucleus, which is essential for monolayer recovery [7]. In
proliferative tumor and leukemia cells, it was also found that
phosphorylated VEGFR2 has a nuclear expression [8,9,10,11,12],
suggesting that molecular mechanisms that contribute to tumor
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nucleus. Taken together, these studies document the presence of
VEGFR2 in the nucleus and suggest that nuclear VEGFR2 might
amplify the angiogenic response. However, the precise activity of
VEGFR2 in the nucleus is unknown.
Here, we demonstrate a previously unrecognized function for
nuclear VEGFR2 as a putative transcription factor that is involved
in the regulation of its own transcription. We show that VEGFR2
binds to and activates its own promoter in vivo in VEGF-activated
EC. Moreover, we observed that this mechanism is blocked by
treating EC with Bevacizumab or Sutent.
Results
VEGFR2 nuclear internalization is a dynamic process in EC
In order to investigate the possible functions of nuclear
VEGFR2 we established an EC model of VEGFR2 over
expression (EC VEGFR2 IRES GFP) using a lentiviral infection
approach. Positively transduced cells were sorted using GFP
expression and VEGFR2 over expression was confirmed by both
immunofluorescence and confocal microscopy (Figure 1A) and
immunoblot analysis (Figure 2A, first panel). By confocal analysis
we found that VEGFR2 expression was increased both in the
cytoplasm and nucleus of EC VEGFR2 IRES GFP, when
compared to untransduced EC or EC transduced with a control
vector (EC IRES GFP), (Figure 1A). Our data suggest that EC
over expressing VEGFR2 results in high levels of this protein that
are not degraded and also accumulate in the nucleus.
We decided to further investigate the nuclear internalization of
VEGFR2 by performing photobleaching studies on living EC to
measure the nuclear turnover of GFP tagged VEGFR2 (Figure 1B,
C). First, we photobleached VEGFR2-GFP in the whole cell nucleus
and then quantified the nuclear fluorescence recovery by time-lapse
imaging. According to our results, a full recovery of the fluorescence
signal was observed within 100 s (Figure 1B, upper panel, and C),
suggesting a rapid turnover of VEGFR2-GFP between the cytoplasm
and the nucleus. By performing studies with several deletion mutants
we have previously found that the tyrosine residues present in the C-
terminal tail do not change the VEGFR2 nuclear localization, in
contrast to others such as 951, 996, 1053 and 1059 [7]. According to
these results, we constructed tyrosine to phenylalanine VEGFR2
point mutants followed by photobleaching studies. Interestingly, we
found that a single point mutation at tyrosine 951 of the VEGFR2
results in a slower turnover rate compared to EC expressing the wild-
type protein, with fluorescence intensity not recovering to its pre-
photobleaching baseline within the duration of the FRAP experiment
(Figure 1B, lower panel, and C). EC expressing mutations in other
tyrosine residues (such as Y1059, Y1054 and Y996) were evaluated
and presented similar recovery kinetics following bleaching when
compared to VEGFR2-GFP cells (Figure 1C).
Taken together, our results suggest that the translocation of
VEGFR2 from the cytoplasm to the nucleus is a rapid and
dynamic process in which the tyrosine residue 951 plays an
important role.
VEGFR2 nuclear internalization is correlated with
transcriptional activity in EC
We tested if increased levels of VEGFR2 modified the levels of
nuclear proteins involved in cell proliferation and survival
processes that are also involved in angiogenic responses: Cyclin
A [13,14], p65 (NFkB), [15,16,17], Sp1 [18,19] and YY1
[20,21,22]. We observed increased levels of Cyclin A, p65 (NFkB)
and Sp1 in the nucleus of EC VEGFR2 IRES GFP, compared to
control EC IRES GFP (Figure 2A). The expression of YY1 was
not significantly altered in the same cells (Figure 2A). Since some
of these nuclear proteins are transcription factors (TFs), we
evaluated whether their nuclear expression levels were mirrored
by a change in their DNA binding activities using EMSA assays.
We found a p65 (NFkB) increased DNA binding activity in the
VEGFR2 over expressing cells, compared to control EC IRES
GFP (Figure 2B, left panel), which is consistent with the increased
p65 protein levels in the nucleus (Figure 2A, right panel).
Interestingly, the DNA binding activity of YY1 was also increased
in EC over expressing VEGFR2 (Figure 2B). These results indicate
that binding activities of several TFs are increased in EC
expressing VEGFR2, suggesting an enhanced transcriptional
activity in these cells. For that reason, we decided to test if the
levels of transcription in EC were also altered when the nuclear
accumulation of VEGFR2 was experimentally reduced. For this,
we took advantage of our previous observation that a neutralizing
antibody against VEGFR1 (6.12 Ab) decreases VEGFR2 levels in
the nucleus [7]. Using a 5-fluorouracil (5-FU) incorporation assay,
we observed that the levels of transcription were decreased after
6.12 Ab treatment, compared to control cells (Figure 2C). Similar
results were obtained when the levels of VEGFR2 were reduced
by using the siRNA technology (Figure 2D). As shown in Figure
S1, a pool of VEGFR2 siRNA oligos used in our experiments
effectively abrogated the VEGFR2 expression as assessed by qRT-
PCR (by 70% compared with the scrambled siRNA oligos).
Taken together, these results suggest that increased VEGFR2
accumulation in the nucleus is correlated with increased
transcription.
Nuclear VEGFR2 interacts with the transcription factor
Sp1 in the nucleus of EC
The above results suggest that the nuclear levels of VEGFR2
could modulate cell transcription and we decided to investigate the
specific role of VEGFR2 in this process. We asked if VEGFR2
interacts with nuclear proteins and if it modulates cell transcrip-
tion. To address this question, VEGFR2 was immunoprecipitated
from EC nuclear extracts and the proteins that directly or
indirectly interacted with VEGFR2 were identified by Mass
Spectrometry (MS) analysis (Figure 3A,B). Approximately 310
proteins were identified with high confidence with the Mascot
algorithm. None of these proteins have an exclusively cytoplasmic
or nuclear localization. Proteins with a Mascot score greater than
200 were listed in Table S1. Analysis of these possible partners
with Ingenuity Pathway Analysis (IPA) identified 95 proteins in 22
enriched categories for biological functions as represented in
Figure 3B. Interestingly, proteins involved in gene expression are
among the most abundant, suggesting that nuclear VEGFR2
could interact with proteins involved in gene transcription.
In order to confirm the data obtained by MS, we performed
immunoblot on nuclear VEGFR2 immunoprecipitates. We
confirmed an interaction between VEGFR2 and Sp1 (Figure 3C).
Interestingly, Sp1 is a transcription factor that regulates multiple
genes important to angiogenesis. The antibody against Sp1 does
not cross-react with other members of the Sp family, indicating a
specific interaction between VEGFR2 and Sp1. Furthermore, we
performed pull-down assays using purified proteins and our results
suggest an interaction between Sp1 and the region containing
amino acids 789 to 1356 of VEGFR2 (Figure 3D).
Nuclear VEGFR2 binds to and activates the VEGFR2
proximal promoter in EC
Since it was previously shown that Sp1 is involved in the
transcriptional regulation of VEGFR2 gene [23,24] and because
VEGFR2 Regulates Its Own Transcription
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25668Figure 1. VEGFR2 nuclear translocation is a rapid process that is affected by the VEGFR2 tyrosine 951. (A) EC, EC IRES GFP and EC
VEGFR2 IRES GFP were cultured in growing media and VEGFR2 overexpression was analysed by immunofluorescence. Cells were stained with a rabbit
anti-human VEGFR2 antibody (Alexa 594). Results shown are representative z-projections of at least three independent experiments. Scale bar: 20 mm.
Right panel shows mean fluorescence intensity of VEGFR2 in the cell nucleus. *p,0.0001. (B and C) FRAP analysis was performed in EC VEGFR2-GFP
and mutants EC VEGFR2(Y1054F/Y1059F)-GFP, EC VEGFR2(Y996F)-GFP and EC VEGFR2(Y951F)-GFP. Fluorescence signal of the entire nucleus was
photobleached with a single 488-nm high intensity laser pulse and subsequent fluorescence recovery was recorded for 280 s. (B) Selected images of
VEGFR2-GFP protein in EC VEGFR2-GFP (upper panel) and EC VEGFR2(Y951F)-GFP (lower panel) before bleaching (steady-state) at the indicated
intervals post-bleaching (from 5 to 100 s). White circles indicate the bleached region. (C) Fluorescence intensity in the bleached region was measured
every 5 s for 280 s and normalized for the initial intensity. Data show results obtained in three independent experiments, with at least ten different
cells analysed in each case. Error bars represent standard deviation (SD).
doi:10.1371/journal.pone.0025668.g001
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VEGFR2 (Figure 3C), we hypothesized that VEGFR2 could be
involved in the regulation of its own transcription. In order to
answer to this question, we decided to investigate if VEGFR2
could bind to its own promoter. Quantitative ChIP assays were
performed on EC, cultured in growing media. We chose a region
of the human VEGFR2 proximal promoter that comprises five Sp1
binding sites between -300/+1 relative to the transcription start
site (Figure 4A). We observed that Sp1 binds to the VEGFR2
proximal promoter (4.2 fold 60.14 increase relative to the control
IgG), (Figure 4B), which was consistent with previous reports
[23,25]. Interestingly, we observed a 13.8 fold 60.55 increase in
binding of VEGFR2 relative to the negative control IgG
(Figure 4B). As expected, when EC are transfected with Sp1
siRNA in order to reduce its expression, the binding of Sp1 to its
promoter is significantly decreased (Figure 4C). Moreover, the
binding of VEGFR2 to its own promoter is abrogated in EC
transfected with VEGFR2 siRNA (Figure 4C). Note that in both
transfections, the expression of Sp1 and VEGFR2 were downreg-
ulated approximately 70% compared with that of scrambled
siRNA-transfected EC (Figure S1). Curiously, we also found that
the binding of Sp1 to VEGFR2 promoter is significantly increased
when the expression of VEGFR2 is downregulated by siRNA. In
contrast, the binding of VEGFR2 to its own promoter is reduced
in EC transfected with Sp1 siRNA (Figure 4C).
In order to confirm that VEGFR2 binds to its own promoter,
we performed EMSA assays using as a probe the same region of
the VEGFR2 proximal promoter analyzed by ChIP. We identified
four complexes (C1–C4) with distinct electrophoretic mobilities
(Figure 4D, lane 2) which did not form when an excess of cold
probe was introduced in the reaction (Figure 4D, lane 4),
establishing their specificity. To evaluate the presence of VEGFR2
in the shifted complexes, we first tried a supershift assay using an
antibody against VEGFR2, which failed to produce any change in
the mobility of the shifted complexes (data not shown). As the
VEGFR2 antibodies were active in immunoprecipitation exper-
Figure 2. VEGFR2 nuclear internalization levels correlate with transcriptional activity of EC. (A) Cytoplasmic (C) and nuclear extracts (N)
from EC IRES GFP and EC VEGFR2 IRES GFP were analysed by Immunoblot with antibodies against VEGFR2, Cyclin A, Sp1, p65, YY1. P-IkB and Lamin B
were used as cytoplasmic and nuclear controls, respectively. (B) Nuclear extracts from EC IRES GFP (lanes 2,7) and EC VEGFR2 IRES GFP (lanes 3,8) were
incubated with NFkB (left panel, lanes 2 and 3) or YY1 (right panel, lanes 7 and 8) radiolabeled probes. Four NFkB (C1–C4) or five YY1 complexes (C1–
C5) are indicated with black arrows. Specific anti-p65 (lane 4) or anti-YY1 (lane 9) were introduced in the binding reaction to analyse the appearance
of a supershift complex (as indicated in both panels) in EC VEGFR2 IRES GFP cells. Using the same cells, a competitive assay using 100x excess of cold
probe of NFkB (lane 5) or YY1 (lane10) was performed. Control lanes 1 and 6 contain only the radiolabeled probes. (C) EC were cultured in growing
media, treated or not with 6.12 Ab for 1 h and incubated with 5-FU for 15 min. (D) EC were cultured in growing media and transfected with
scrambled siRNA or VEGFR2 siRNA. EC were incubated with 5-FU for 15 min. (C and D) 24 post-transfection. Cells were fixed and sequentially labeled
on the same slide with a rabbit anti-human VEGFR2 (red fluorescence) and a mouse anti-human BrdU antibody (green fluorescence) and analysed by
confocal microscopy. Results shown are representative z-projections of three independent experiments. Scale bar: 20 mm.
doi:10.1371/journal.pone.0025668.g002
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presence of VEGFR2 in the shifted complexes. Using these
VEGFR2-immunodepleted nuclear extracts in the EMSA assays
we observed an absence of the C2 complex and a strong reduction
in the intensity of the C1 complex while the C3 and C4 complexes
were not significantly altered (Figure 4D, lane 3). An IgG-depleted
control extract did not affect the intensity of these complexes
(Figure S2B). Simultaneously, the VEGFR2 depletion in the
protein extracts was confirmed by immunoblot (Figure S2A).
These results are consistent with the presence of VEGFR2 in the
C1 and C2 complexes. A similar experiment performed using Sp1-
depleted extract showed a decrease in the intensity of C1 and C2
complexes (Figure S2B), suggesting that Sp1 and VEGFR2 are
present in the same DNA/protein complexes.
Finally, we investigated the ability of the nuclear VEGFR2 to
transcriptionally activate its own promoter using luciferase
Figure 3. Nuclear VEGFR2 interacts with the transcription factor Sp1 in the nucleus of EC. (A) Immunoprecipitation (IP) of 1 mg EC nuclear
extract with anti-human VEGFR2 was performed and resolved in 8% SDS-PAGE, following silver staining (lane 2). VEGFR2 antibody plus beads
(without N) were used as negative control for immunoprecipitation (lane 1). The protein marker is shown as molecular weight (MW) in thousands. (B)
Representation of the mass spectrometry analysis of the nuclear VEGFR2 IP, showing the categories for the different biological functions of the
identified proteins (p,0.05). (C) Immunoprecipitation (IP) of EC nuclear extracts (N) was conducted with the VEGFR2 (lane 2), Sp1 (lane 4) and rabbit
IgG (rIgG-lane 5) antibodies followed by VEGFR2 (upper panel) or Sp1 (lower panel) immunoblotting. VEGFR2 (lane 1) or Sp1 (lane 3) antibodies plus
beads (without N) were used as negative controls for immunoprecipitation. Non-immunoprecipitated nuclear cell extract (lane 6) was also included in
the experiment. (D) Pull-down assay: Sp1 protein fused to a HA tag was incubated with GST alone (lanes 1 and 2) or VEGFR2 (789-1356)-GST (lanes 3
and 4). GST-unbound (UB) (lanes 1 and 3) and bound (B) fractions (lanes 2 and 4) were loaded and analyzed with GST (upper panel) and Sp1 (lower
panel) antibodies.
doi:10.1371/journal.pone.0025668.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25668Figure 4. Nuclear VEGFR2 binds to the VEGFR2 proximal promoter in EC. (A) Sequence of the human VEGFR2 proximal promoter (retrieved
from Ensemble database accession number: ENSG00000128052) and outline of putative Sp1 binding sites. The transcription start site is indicated in
gray. (B) ChIP assays of the VEGFR2 proximal promoter were performed using EC cultured in growing media. Antibodies against VEGFR2 and Sp1 were
used. Normal rabbit/mouse IgG were used as control. Also, an antibody for RNA Pol II was used to test the promoter activity. All values are relative to
control IgG background and normalized to an intergenic region. Data are mean 6 s.e.m. of triplicates and represents three independent experiments.
(C) ChIP assays of the VEGFR2 proximal promoter were performed in EC 24 h post-transfection of scrambled siRNA or VEGFR2 siRNA or Sp1 siRNA.
Antibodies against VEGFR2 and Sp1 were used. Normal rabbit IgG was used as control. Values are relative to control IgG background and normalized
to an intergenic region. Data are mean 6 s.e.m. of triplicates and represents three independent experiments. (D) EMSA analysis of the VEGFR2
promoter with EC nuclear extracts (lane 2) or VEGFR2 immunodepleted (ID VEGFR2) extract (lane 3) were conducted. Four complexes (C1-C4) are
VEGFR2 Regulates Its Own Transcription
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GFP cells, which constitutively express VEGFR2, and compared
to control 3T3 GFP cells that do not express VEGFR2 [7].
Transfection of a pGL3 control vector alone did not produce
significant differences in luciferase activities in both cell lines
(Figure 5A). However, when we transfected a construct including
the VEGFR2 proximal promoter spanning -300/+1, we observed a
significantly higher luciferase activity in the VEGFR2-GFP cells
(4.8 fold 60.88, p=0.007) compared to control cells (2.4 fold
60.22), (Figure 5A). In accordance, we confirmed a reduction in
luciferase activity in VEGFR2-GFP cells cotransfected with
VEGFR2 siRNA when compared to scrambled siRNA-cotrans-
fected cells (Figure 5B). Moreover, no increased luciferase activity
over basal levels (1.74 fold 60.8) was observed in the 3T3
VEGFR2-GFP cells, when transfected with a reporter construct
containing a shorter fragment (-116/+1) of the VEGFR2 promoter
(Figure 5A). These results suggest that VEGFR2 is indeed able to
activate transcription from its own promoter and that this
activation requires the region between -300/-116 relative to the
transcription start site. Consistent with the observed decrease in
VEGFR2 binding to its own promoter when the expression of Sp1
is reduced by siRNA (Figure 3C), we also observed a significant
decrease of the luciferase activity in VEGFR2-GFP cells
cotransfected with Sp1 siRNA (Figure 5B).
Taken together, these data strongly suggest a previously
unrecognized function of nuclear VEGFR2 as a possible
transcription factor involved in the regulation of its own
transcription.
VEGFR2 binding to its own promoter is dependent of
VEGFR2 activation
To further analyze the possible functional relevance of the
VEGFR2 binding to its own promoter, we took advantage of our
finding that VEGFR2 nuclear translocation requires activation by
VEGF [7]. We did not observe DNA binding of VEGFR2 (0.2
fold 60.03) when EC were cultured under basal medium (without
supplements or serum), which is consistent with the absence of
nuclear VEGFR2 in these culture conditions [7]. Also, the Sp1
binding was negligible under these conditions (2.3 fold 60.13),
(Figure 6A). However, after 30 min of VEGF stimulation, we
observed a strong increase in binding of VEGFR2 (159.6 fold
65.21) to its own promoter (Figure 6A). In the same cells, we
failed to observe an increment of Sp1 binding (1.03 fold 60.17,
relative to control IgG), (Figure 6A). These results demonstrate
that VEGFR2 activation by VEGF is crucial for VEGFR2 binding
to its own promoter in vivo, suggesting that VEGFR2, as a nuclear
protein, could be involved in amplifying the angiogenic response.
To further explore this idea, we treated the EC with two anti-
angiogenic agents, which block the VEGFR2 activation, in order
to evaluate their effect on VEGFR2 binding to its own promoter.
Our results showed that both Bevacizumab, a monoclonal
antibody against VEGF and Sunitinib which inhibits VEGFR,
PDGFR and c-KIT signaling, led to a strong reduction of the
binding of VEGFR2 to its own promoter, as estimated by
quantitative ChIP (Figure 6B). As a control, ECs were also treated
with Iressa, an inhibitor of epidermal growth factor receptor
(EGFR) that has no effect on VEGFR2 activation. Our results
(Figure S3) show that Iressa has no effects on VEGFR2 binding to
its own promoter.
Taken together, our results suggest that anti-angiogenic agents
that block VEGFR2 activation significantly decrease the level of
VEGFR2 DNA binding activity.
Discussion
The classical view of signaling through VEGFR2 considers that
the membrane receptor is phosphorylated upon ligand binding,
activating intracellular signaling cascades that regulate a wide
range of biological outcomes, including cellular survival, prolifer-
ation, migration and differentiation [2]. Until recently, internal-
ization of VEGFR2 was thought to be the pathway for
downregulation of the signaling through receptor degradation.
Consistent with this, it was found that VEGFR2 is ubiquitylated by
c-Cbl [26] and that activated PKC marks the receptor for
internalization and degradation [27]. However, increasing evi-
dence indicates that internalized VEGFR2 may also have
signaling activity. For instance, it has been shown that phosphor-
ylated VEGFR2 can be internalized in a VE-cadherin-dependent
manner to endosomal compartments, retaining activation of
signaling pathways and sustaining cell proliferation and migration,
rather than receptor degradation [28]. Recently, it was shown that
ephrin-B2 activation controls VEGFR2 internalization, which is
required for activation and downstream signaling of the receptor
during vascular sprouting in physiological and pathological
conditions [29,30]. We also demonstrated that the nuclear
internalization of VEGFR2 is required for endothelial recovery
following injury [7]. Finally, we and others found constitutive
nuclear localization of VEGFR2 in proliferative tumor cells,
suggesting that this protein may be involved in nuclear molecular
mechanisms that contribute to tumor progression [8,9,10,11,12].
Taken together, these different studies suggest that the intracellular
trafficking of VEGFR2 is linked to its signaling activity that
contributes to the amplification of the angiogenic response.
The mechanism by which VEGFR2 translocates to the nucleus
is not yet completely understood. VEGFR2 may be internalized
preferentially via a caveolar pathway and transported to
perinuclear caveosomes [31,32,33,34]. In support of this, we and
others found that VEGFR2 colocalized with caveolin-1 [7,35]. It is
known that caveolae are transported from the membrane to
intracellular organelles along microtubules [36] and dynamin-2, a
well-established regulator of caveolar endocytosis, seems to require
interactions with functional microtubules to stimulate its GTPase
activity and promote vesicular transport [37,38,39,40]. This is
consistent with our finding that drugs inhibiting microtubule
polymerization blocked the internalization of VEGF-VEGFR2
complex [7]. It was also reported that inhibitors of dynamin-2
blocked the VEGF-induced internalization of VEGFR2, resulting
in decreased tip EC filopodia extensions [29]. From caveosomes,
internalized cargo may be delivered to the endoplasmic reticulum
providing a transport pathway to the nucleus. Our previous
findings [7], suggest that VEGFR2 nuclear internalization requires
the nuclear pore complex (NPC) since an accumulation of
VEGFR2 is observed after treating EC with an inhibitor of the
NPC. The typical mechanism for the import through the NPC is
mediated by the binding of the protein nuclear localization signals
(NLS) to importin a and b to form a complex that interacts with
NPC so that the protein can enter the nucleoplasm [41]. However,
the presence of NLS in VEGFR2 sequence was neither described
nor identified in the bioinformatics analyses performed by us.
indicated with black arrows. A competitive assay using 100x excess of cold probe of VEGFR2 promoter was conducted (lane 4) using EC nuclear
extract. Control lane 1 contains only the radiolabeled probe.
doi:10.1371/journal.pone.0025668.g004
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internalization could also apply to VEGFR2. FGFR1, which is
also devoid of a NLS, is chaperoned to the nucleus by its ligand
FGF2. The binding of FGF2, which harbors NLS sequences,
results in the nuclear translocation of the receptor-ligand complex
in an importin a-dependent manner [42]. VEGF has five potential
NLS sequences in the C-terminal region [43] and it is possible that
they drive the complex VEGF-VEGFR2 through the NPC to the
nucleus.
In the present report we have shown in living EC that VEGFR2
rapidly translocates to the nucleus and the VEGFR2 tyrosine
residue 951 plays an important role in this dynamic process. The
role that VEGFR2 might play in the nucleus has remained
undisclosed. Here, we show for the first time to our knowledge that
nuclear VEGFR2 has transcriptional activity. In particular, we
show that VEGFR2 binds to its own promoter in VEGFR2-
activated EC in vivo and that VEGFR2 can activate transcription
from this promoter in reporter assays. These findings suggest that
VEGFR2 might participate in the positive feedback regulation of
its own expression. This is consistent with previous reports
showing that VEGF binding to membrane VEGFR2 results in
increased levels of VEGFR2 gene transcription and protein
expression [44]. Similarly, it was observed that mechanoactivation
produces translocation of VEGFR2 to the nucleus [45], which is
accompanied by an up-regulation of the VEGFR2 gene transcrip-
tion [46].
Our results now indicate that this increase in VEGFR2
expression depends, at least in part on VEGFR2 transcriptional
activity. Our EMSA data revealed the existence of different
VEGFR2 containing complexes (C1 and C2 complexes) with
different mobilities when bound to the promoter, suggesting that
VEGFR2 interacts with additional molecules when bound to
DNA. Our MS profiling data seems to support this idea. In
particular, Sp1 stands out as one of the VEGFR2-interacting
proteins in the nucleus of EC. This is consistent with previous data
showing that Sp1 is implicated in the transcriptional regulation of
genes important to angiogenesis, including, VEGF and VEGFR2
[23,24,47]. Co-immunoprecipitation experiments showed that
Sp1 and VEGFR2 interact. Pull-down assay experiments using
purified proteins further confirmed that the interaction between
Figure 5. Nuclear VEGFR2 activates the human VEGFR2 proximal promoter. (A) NIH 3T3 GFP and NIH 3T3 VEGFR2-GFP were transfected with
pGL3 control or pGL3 VEGFR2 (-300/+1) or pGL3 VEGFR2 (-116/+1). The b-gal plasmid was co-transfected as a control. Promoter activities were
measured with luciferase activity normalized to b-gal. The results are expressed as the relative luciferase activities. Data are mean 6 s.e.m. of relative
luciferase activities from four independent experiments, each performed in triplicate. *p=0.007; **p=0.001). (B) NIH 3T3 VEGFR2-GFP were
transfected with scrambled siRNA, VEGFR2 siRNA or Sp1 siRNA. At 48 h post-transfection the relative luciferase activity of pGL3 control or pGL3
VEGFR2 (-300/+1) was measured. Data are mean 6 s.e.m. of relative luciferase activities from three independent experiments, each performed in
triplicate, (*p =0.003).
doi:10.1371/journal.pone.0025668.g005
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VEGFR2 depleted extracts also indicate that Sp1 and VEGFR2
are present in the same protein-DNA complexes. Interestingly, the
-300/+1 bp region of the VEGFR2 promoter, identified as one of
the key elements for the regulation of VEGFR2 expression
[24,25,48,49], contains five Sp1 binding sites and is able to bind
both Sp1 and VEGFR2. Our reporter assays show that the region
between -300/-116 relative to transcription start site is essential to
confer the VEGFR2 promoter VEGFR2-dependent transcriptional
activity. Moreover, our results indicate that VEGFR2 is essential
for the activity of its own promoter since cells that do not express
VEGFR2 have significantly lower levels of the VEGFR2 promoter
activity compared to VEGFR2-expressing cells. Accordingly, the
levels of the VEGFR2 promoter activity observed in VEGFR2-
expressing cells are significantly decreased if the expression of
VEGFR2 is reduced by siRNA. A definitive proof of VEGFR2
transcriptional activity would require a direct analysis of the
endogenous VEGFR2 locus. This could be overcome by generating
EC carrying a reporter gene (e.g GFP) knocked-in into the
VEGFR2 locus. A recently developed technology, which allows
homologous recombination in somatic cells using recombinant
Adeno-Associated Virus (rAAV), might facilitate the establishment
of such a reporter line [50,51,52]. In this system, the reduction of
the GFP reporter gene transcripts following VEGFR2 siRNA
experiments would confirm the VEGFR2-mediated transcription-
al activity on the endogenous locus.
However, at the moment we do not know if VEGFR2 binds to a
consensus DNA sequence and the nature of this sequence. Clearly,
identification of other transcriptional targets of VEGFR2 will help
to address this issue. Also, understanding the mechanism of
VEGFR2 transcriptional activity will require the complete
identification of the molecules interacting with VEGFR2 at the
Figure 6. VEGFR2 binding to its own promoter is dependent of VEGFR2 activation. ChIP assays of the VEGFR2 proximal promoter were
performed using (A) EC cultured in basal medium for 48 h, and stimulated or not with VEGF (20 ng/ml) for 30 min. Antibodies against VEGFR2 and
Sp1 were used. Normal rabbit/mouse IgG were used as control. Also, an antibody for RNA Pol II was used to test the promoter activity. Values are
relative to control IgG background and normalized to an intergenic region. Data are mean 6 s.e.m. of triplicates and represents three independent
experiments. (B) EC cultured in growing media were treated or not with 0.5 mg/ml Bevacizumab (left panel) or 0.1 mM Sunitinib (right panel) for 16 h.
In the Sunitinib experiments, DMSO was used as vehicle. ChIP values are relative to control IgG and normalized to an intergenic region. Data are
mean 6 s.e.m. of triplicates and represents three independent experiments.
doi:10.1371/journal.pone.0025668.g006
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requires VEGF-activation, since this binding cannot be detected in
EC cultured in the absence of this growth factor. Moreover, EC
treated with anti-angiogenic agents that block VEGFR2 activation
present negligible levels of VEGFR2 DNA binding activity. This is
consistent with the finding that the nuclear translocation of the
receptor is dependent of VEGF activation [7], and further
supports the idea that nuclear translocation/transcriptional
activity of VEGFR2 is an integral part of the signaling mediated
by this receptor.
While in EC VEGFR2 nuclear translocation and consequently
its DNA binding depends on VEGFR2 activation by VEGF, it has
been reported that some tumor cells present constitutive nuclear
localization of VEGFR2. If these tumor cells also present
constitutive VEGFR2 transcriptional activity, this could be an
additional mechanism that plays a role in tumor angiogenesis.
Therefore, the analysis of VEGFR2 transcriptional activity in
those tumors and the identification of the target genes will surely
help to better understand its putative role in tumor angiogenesis
and to devise novel therapeutic approaches.
In conclusion, our findings provide novel insights into the role of
VEGFR2 as a nuclear protein. Here, we demonstrate that in
VEGF-activated EC, nuclear VEGFR2 may act as a transcription
factor by binding to and activating its own promoter. By this
mechanism nuclear VEGFR2 could be involved in amplifying the
angiogenic response.
Materials and Methods
Reagents
VEGF (20 ng/ml) was purchased from Sigma-Aldrich, USA.
Bevacizumab (AvastinH, Genentech/ Roche, USA), (0.5 mg/ml)
was provided by the Oncology Service of Santa Maria Hospital.
Sunitinib (0.1 mM) was provided by Pfizer International, USA.
Iressa (0.1 mM) was purchased from Tocris Bioscience, UK. 5-
fluorouracil (5-FU, 2 mM) was purchased from Sigma-Aldrich,
USA.
Cell culture
Primary Human Umbilical Vein Endothelial Cells (EC) were
kindly provided by Dr Shahin Rafii (Cornell University Medical
College, New York, USA). EC, passage 4–8, were cultured in
0.02% gelatin-coated dishes in growing endothelial medium (basal
EBM-2 medium supplemented with EGM-2 singlequots, BBE and
5% of Fetal Bovine Serum (FBS)) as provided by the manufac-
turers (Lonza, USA). In basal media experiments, upon reaching
confluence EC were cultured in basal EBM-2 medium for 48 h.
HEK-293 T cells were cultured in DMEM (Invitrogen Corpora-
tion, USA) supplemented with 10% FBS. NIH 3T3 GFP and NIH
3T3 VEGFR2-GFP cells were described and characterized in [7]
and were cultured in DMEM supplemented with 10% FBS and
800 mg/ml Neomycin-G418 (Invitrogen Corporation, USA).
Construction of the VEGFR2 point mutants by site
directed-mutagenesis
Tyrosine to phenylalanine VEGFR2 point mutants were
generated by site-directed mutagenesis using the overlap extension
method. Two separate amplification reactions were first per-
formed using the pEGFP-VEGFR2 as template; one using the
primer A: 59 C GTC ATG GAT CCA GAT GAA CTC C 39
(sense) and the mutated antisense primer (listed below), the other
using the mutated sense primer (listed below) and the primer B: 59
TA G GT CAG GGT GGT CAC GAG 39 (antisense).
The mutated primers designed to replace tyrosine (Y) to
phenylalanine (F-bold) residues in Y951 were: 59 GGG AAA GAC
TTC GTT GGA GCA 39 (sense) and 59 TGC TCC AAC GAA
GTC TTT CCC 39 (antisense); in Y996 were 59 T CCT GAA
GAT CTG TTT AAG GAC TTC CTG 39 (sense) and 59 G GAA
GTC CTT AAA CAG ATC TTC AG 39 (antisense); in Y1054
were 59 GCC CGG GAT ATT TTT AAA GAT CCA G 39(sense)
and 59 TGG ATC TTT AAA AAT ATC CCG GGC C 39
(antisense); in Y1059 were 59 GAT CCA GAT TTT GTC AGA
AAA GGA G 39 (sense) and 59 C TCC TTT TCT GAC AAA
ATC TGG ATC T 39 (antisense).
The thermal amplification conditions were 95uC/5 min, 35
cycles (95uC/1 min, 61uC/1 min, 72uC/1 min), 72uC/10 min.
An overlapping reaction was performed using the mutated
products from the first PCR (2–5%) and the sense A and antisense
B primers. The thermal amplification conditions were 95uC/
5 min, 35 cycles (95uC/1 min, 58uC/1 min, 72uC/1 min), 72uC/
10 min. PCR products were inserted into the BamHI/ ApaI sites of
pEGFP-VEGFR2. All constructs were confirmed by DNA
sequencing.
Generation of Lentiviral vectors expressing VEGFR2
The VEGFR2 WT and tyrosine to phenylalanine mutants fused
to GFP were released from pEGFP-VEGFR2 using the SalI/ HpaI
restriction sites and were cloned in the lentiviral plasmid FUGW
(kindly given by Dr. Pedro Simas, Instituto de Medicina
Molecular, Lisbon, Portugal) in the BamHI/ EcoRI restriction
sites, using blunt-end cloning, generating FU-VEGFR2-GFP. All
constructs were confirmed by DNA sequencing. The lentiviral
vector FU IRES GFP was generated by replacing the GFP of
FUGW with the IRES GFP from pIRES GFP (Stratagene Inc.,
USA). FU-VEGFR2 IRES GFP was generated by releasing full
length VEGFR2 from pSP73-VEGFR2 using KpnI/ XhoI
restriction sites and cloned in FU IRES GFP using the BamHI
restriction site by blunt-end cloning. All constructs were confirmed
by DNA sequencing.
Lentiviral Production
Lentiviral particles were obtained with the transfection of HEK-
293T cells using a standard calcium phosphate precipitation
protocol. HEK-293T cells (<50% confluent) were transfected with
the lentiviral vector plasmids FUGW, FU VEGFR2-GFP
(VEGFR2 WT or tyrosine to phenylalanine mutants), FU IRES
GFP or FU-VEGFR2 IRES GFP together with the HIV-1
packaging vector Delta 8.9 and the VSV-g envelope glycoprotein.
The viral supernatants were collected 60 h post-transfection and
filtered through a 0.45 mm pore size filter. EC were seeded at
7.5610
4 cells (12 well plate) 24 h before transduction and then
exposed to 500 ml of virus supernatant (supplemented with
polybrene to a final concentration of 4 mg/ ml). 72 h post-
infection the GFP positive cells were sorted by FACS Aria (Becton,
Dickinson and Company, USA). EC expressing FUGW were
named EC GFP; EC expressing FU-VEGFR2(WT)-GFP were
named EC VEGFR2-GFP; EC expressing FU-VEGFR2(Y1054F/
Y1059F)-GFP were named EC VEGFR2(Y1054F/Y1059F)-GFP;
EC expressing FU-VEGFR2(Y996F)-GFP were named EC
VEGFR2(Y996F)-GFP; EC expressing FU-VEGFR2(Y951F)-
GFP were named EC VEGFR2(Y951F)-GFP; EC expressing FU
IRES GFP were named EC IRES GFP; EC expressing FU-
VEGFR2 IRES GFP were named EC VEGFR2 IRES GFP.
Immunofluorescence and Confocal Microscopy
EC were cultured on gelatin-coated glass coverslips. The cells
were fixed in 1% (v/v) formaldehyde/ PBS, for 10 min, at 4uC
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X-100 plus 5% (v/v) normal serum, cells were incubated in
different conditions with the following antibodies: VEGFR2 (Santa
Cruz Biotechnology, USA) at 4uC, overnight, followed by
incubation with Alexa Fluor 594 (Molecular Probes, Invitrogen
Corporation, USA) for an additional hour, at room temperature or
BrdU (Sigma-Aldrich, USA), for 30 min, at room temperature,
followed by incubation with Alexa Fluor 488 (Molecular Probes,
Invitrogen Corporation, USA) for additional 30 min, at room
temperature. The samples were mounted in Vectashield (Vector
Laboratories, USA) and analyzed by confocal microscopy. Sets of
optical sections of 5 mm intervals along the Z-axis (from bottom to
top of cells) were acquired on a Zeiss LSM 510 META (Carl Zeiss,
Germany) inverted laser scanning confocal microscope using a
PlanApochromat 63x/1.4 oil immersion objective. Alexa Fluor
488 and GFP fluorescence were detected using the 488 nm line of
an Ar laser (45 mW nominal output) and a BP 505–550 nm filter.
Alexa Fluor 594 fluorescence was detected using a 594 nm HeNe
laser (2 mW nominal output) and a LP 615 nm filter. Potential
bleed-through from the different fluorophores was avoided by
performing sequential multi-track/frame imaging sequences. Z-
projections were obtained using ImageJ (http://rsbweb.nih.gov/
ij/).
Live cell imaging was performed at 37uC and 5% CO2 on a
Zeiss LSM 510 META (Carl Zeiss, Germany) inverted laser
scanning confocal microscope equipped with a large incubator for
temperature control and a stage incubator for CO2 supply (PeCon,
Germany).
Fluorescence Recovery After Photobleaching (FRAP)
Each FRAP analysis started with a single image scan followed
by a bleach pulse at 100% laser power in a region of interest (ROI)
that coincided with the cell nucleus (,350 mm
2 area). A series of
56 single-section images were then acquired at 5 s intervals for
280 s, with the first image being acquired 2 ms after the end of the
photobleaching. Image acquisition was performed with laser
power attenuated to 1% of the bleaching intensity.
Fluorescence intensity quantification was performed for each
FRAP time series using ImageJ software (http://rsbweb.nih.gov.
ij). The average fluorescence in the nucleus of bleached cells I(t)
and the total cell fluorescence T(t) were calculated for each
background-subtracted image at time t. FRAP curves for bleached
cells were then normalized and corrected for loss of fluorescence
due to imaging,
I Nt ðÞ ~It ðÞ =I0:T0=Tt ðÞ
where I0 and T0 are the nuclear and total fluorescence intensities
before bleaching started [53].
5-FU incorporation
EC were cultured in growing media on gelatin-coated glass
coverslips, treated with 6.12 Ab (1 mg/ml) and scrambled or
VEGFR2 siRNA following incubation with 5-FU (2 mM) for
15 min. The cells were fixed, permeabilized, and labeled
sequentially for BrdU and VEGFR2 according to the immuno-
fluorescence protocol described above.
RNA interference
SMART pool siRNA targeting human VEGFR2 or human Sp1
and non-targeting pool siRNA (scrambled siRNA) were purchased
from Dharmacon (UK). Knockdown of VEGFR2 or Sp1 was
performed according to the manufacturer’s recommendation.
Briefly, EC were transfected with VEGFR2, Sp1 or scrambled
siRNA (50 nM) using the Dharmafect 4 reagent (Dharmacon,
UK). After 24 h, cells were used in qRT-PCR, ChIP, 5FU-
incorporation or luciferase assays.
Cell Fractionation and Immunoblot Analysis
Nuclear and cytoplasmic protein extracts were prepared as
described [7]. Equal amounts of protein extracts were separated
by SDS–PAGE, transferred to nitrocellulose and probed with
antibodies against VEGFR2, P-IkB (both from Cell Signaling
Technology Inc., USA), Cyclin A, Sp1, p65, YY1, Lamin B (all
from Santa Cruz Biotecnology, USA).
Immunoprecipitation
Nuclear extracts were pre-cleared with 25 ml of protein G-
Sepharose beads (Sigma-Aldrich, USA). Nuclear protein superna-
tants were incubated with antibodies against VEGFR2 (Cell
Signaling Technology Inc., USA) or Sp1 (Santa Cruz Biotecnol-
ogy, USA) and rabbit control IgG (Santa Cruz Biotecnology, USA)
overnight, at 4uC, and incubated with protein G-Sepharose beads
for an additional hour, at 4uC. Beads were washed once in a lysis
buffer containing 500 mM NaCl and twice in a lysis buffer
containing 150 mM NaCl. Beads were resuspended in SDS
loading buffer and boiled for 5 min. Samples were separated by
SDS-PAGE followed by Immunoblot analysis or silver staining for
mass spectrometry analysis.
Pull-down assays
The GST fusion protein containing amino acids between 789-
1356 of human VEGFR2 (VEGFR2 (789-1356)-GST) was
purchased from Sigma-Aldrich, USA. The Sp1 protein fused to
a HA tag (Sp1-HA) was obtained from Enzo Life Sciences, USA.
For pull-down assays, 3 mg of Sp1-HA were incubated with
glutathione-sepharose 4B beads (GE Healthcare, USA) for 1 h, at
4uC, in binding buffer containing 50 mM Tris-HCl pH 7.5,
150 mM NaCl, 10% Glicerol, 1% NP-40, 1 mM orthovanadate
and complete protease inhibitors. The beads were spin down and
the pre-cleared supernatant was incubated with 3 mg of purified
GST or VEGFR2 (789-1356)-GST proteins overnight, at 4uC.
Peptide complexes were recovered with 20 ml of glutathione-
sepharose beads for 1 h, at 4uC. The supernatants were kept as the
unbound fractions (UB) and the beads were washed eight times in
the binding buffer. Protein were eluted from the beads in reducing
laemmli’s buffer, resolved by SDS-PAGE, transferred to nitrocel-
lulose and analyzed by Immunoblot with the indicated antibodies.
Mass spectrometry
1D SDS-PAGE gel lanes were cut into 2-mm slices using an
automatic gel slicer and subjected to in-gel reduction with
dithiothreitol, alkylation with iodoacetamide and digestion with
trypsin (Promega Corporation, USA, sequencing grade), essen-
tially as described [54]. Nanoflow LC-MS/MS was performed on
an 1100 series capillary LC system (Agilent Technologies, USA)
coupled to an LTQ linear ion trap mass spectrometer (Thermo
Fisher Scientific Inc., USA) operating in positive mode and
equipped with a nanospray source. Peptide mixtures were trapped
on a ReproSil C18 reversed phase column (Dr Maisch GmbH;
column dimensions 1.5 cm6100 mm, packed in-house) at a flow
rate of 8 ml/min. Peptide separation was performed on ReproSil
C18 reversed phase column (Dr Maisch GmbH; column
dimensions 15 cm650 mm, packed in-house) using a linear
gradient from 0 to 80% B (A=0.1% formic acid; B=80% (v/v)
acetonitrile, 0.1% formic acid) in 70 min and at a constant flow
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sprayed into the ESI source of the mass spectrometer. Mass
spectra were acquired in continuum mode; fragmentation of the
peptides was performed in data-dependent mode. Peak lists were
automatically created from raw data files using the Mascot
Distiller software (version 2.1; MatrixScience). The Mascot search
algorithm (version 2.2, MatrixScience) was used for searching
against the SwissProt database (release SwissProt_54.8.fasta;
taxonomy: mammalian). The peptide tolerance was typically set
to 2 Da and the fragment ion tolerance was set to 0.8 Da. A
maximum number of 2 missed cleavages by trypsin were allowed
and carbamidomethylated cysteine and oxidized methionine were
set as fixed and variable modifications, respectively. The Mascot
score cut-off value for a positive protein hit was set to 60.
Individual peptide MS/MS spectra with Mascot scores below 40
were checked manually and either interpreted as valid identifica-
tions or discarded. Typical contaminants, also present in
immunopurifications using beads coated with pre-immune serum
or antibodies directed against irrelevant proteins were omitted
from the table. The proteins identified were further analyzed with
the Ingenuity Pathway Analysis Software (Ingenuity Systems, Inc.,
USA) and clustered according to their involvement in different
biological functions. The enriched categories obtained were
represented according to their p-value.
Chromatin Immunoprecipitation (ChIP)
5610
8 EC were fixed with 1% formaldehyde for 10 min at
37uC and subjected to quantitative ChIP analysis as previously
described [55]. Briefly, 5 mg of the specific antibodies were pre-
bound overnight, at 4uC, to protein G-Dynal magnetic beads
(Invitrogen Corporation, USA), added to the diluted sonicated
chromatin (4x 20 s, 50% output in Soniprep 150, Sanyo) and
immunoprecipitated overnight, at 4uC. Antibodies used were as
follows: VEGFR2 (Cell Signaling Tecnology, Inc., USA), Sp1
(Santa Cruz Biotechnology, USA), RNA Polymerase II (Covance,
USA) and Rabbit/Mouse IgG (Santa Cruz Biotechonology, USA).
The magnetic bead-chromatin complexes were collected and
washed in RIPA buffer (containing 50 mM HEPES pH 7.6,
1 mM EDTA, 0.7% Na deoxycholate, 1% NP-40, 500 mM LiCl).
Chromatin-protein complexes were further washed in 1x TE
buffer, eluted from beads in 1% SDS, 100 mM NaHCO3 and
heated overnight at 65uC to reverse the formaldehyde cross-
linking. DNA fragments were purified with a QIAquick Spin Kit
(QIAGEN, Germany). The DNA amount of VEGFR2 gene
immunoprecipitated was quantified by RT-PCR using primers
designed for the amplification of the VEGFR2 proximal promoter
(-300/-159 relative to the transcription start site). The primers
used were as follows: 59 CCGGCAAGCGATTAAATCTTG-
GAG 39 (sense) and 59 TTTCCCCACACAACTGGACTGC 39
(antisense). Additionally were used primers for the amplification of
an intergenic region in chromosome 10 as described [57]. The
PCR reaction mixture used was as follows for a 25 ml total volume:
1x SybrGreen (Applied Biosystems, USA), 100 nM of each
primer, and 2.5 ml of each ChIP DNA sample (input 1:10). All
reactions were performed and analysed as triplicates using a Fast
7500 Real time PCR (Applied Biosystems, USA). The results were
normalized based on the {Delta}{Delta}Ct method as previously
described [55,56,57]. Briefly, the threshold cycles (Ct) from total
input samples were subtracted from the Ct of the IgG control and
from the experimental IP (VEGFR2, Sp1 and RNA Pol II). The
fold difference between the corrected value for the total input and
corrected experimental IP value was calculated as 2{Delta}{Del-
ta}Ct. The fold difference over background obtained for VEGFR2
promoter was further normalized to the value obtained for the
intergenic region.
Quantitative RT-PCR
Total RNA and cDNA were prepared and quantitative RT-
PCR (qRT-PCR) was performed as described [58]. VEGFR2
primer sequences were as follows: 59 ATTCCTCCCCCG-
CATCA 39 (sense) and 59 GCTCGTTGGCGCACTCTT 39
(antisense).
Sp1 primer sequences were as follows: 59 TCGGATGAGCTA-
CAGAGGCACAAA 39 (sense) and 59 AAAGTGCCCACACT-
CAGAGCTACA 39 (antisense).
Electroforetic mobility shift assays (EMSA) and
Immunodepleting EMSA (IDEMSA)
The oligonucleotides including consensus recognition sequence
for TFs YY1, NFkB and Sp1 are derived from Transcruz gel shift
oligonucleotides (SantaCruz Biotechnology, USA). A DNA probe
comprising the same region of the VEGFR2 promoter (-300/-159)
amplified in ChIP assays was also used. EMSAs were performed
following standard methodology as described [10]. Probes were
labeled with c-ATP 32P (Perkin Elmer, USA) and incubated for
20 min at room temperature with 10 mg of EC nuclear extracts in
a binding buffer (containing 10 mM HEPES, 4% Ficoll, 70 nM
NaCl, 2 mM DTT, 100 mg/mL bovine serum albumin and 0.01%
NP40). For competition assays, a 100-fold molar excess of
unlabeled probe was incubated in the binding reaction. For
supershift assays, 1 mg of the p65 or YY1 was added to the binding
reaction for an additional 30 min at room temperature. DNA-
protein complexes were resolved in 5% non-denaturating poly-
acrilamide gels. IDEMSAs were performed as described [59].
Briefly, 30 mg of EC nuclear extracts were depleted of VEGFR2
by immunoprecipitation with anti-human VEGFR2 antibody for
1 h followed by incubation with sepharose beads for an additional
hour, at 4uC. After centrifugation, 10 mg of the VEGFR2
immunodepleted supernantant were used for each reaction of
EMSA/Supershift as described above.
Luciferase reporter assays
The proximal promoter of VEGFR2 gene was amplified from
genomic DNA by PCR and cloned into a pGL3-promoter firefly
luciferase vector (Promega Corporation, USA). Briefly, the
sequence from -300/+1 of the VEGFR2 proximal promoter was
amplified using oligonucleotides with flanking restriction enzyme
sites 59 Xho I and 39 Bgl II. The primers used were as follows: 59
AAGCTCTCGAGGGTTAATTAAGACCGGCAAGCGATT-
AAATCTTGGAG 39 (sense) and 59 AGATCTTTAGATCTG-
TAGCAGGGTGGGAGCTGGTGCCGA 39 (antisense). A dele-
tion fragment of the region from 2116/+1 bp of the VEGFR2
promoter was obtained using the same procedure. The primer
used was as follows: 59 AGCTCTCGAGGGTTAATTAAGG-
TACCCGGGTGAGGGGCCGGGCT 39 (sense). All constructs
were confirmed by DNA sequencing. For luciferase reporter gene
assays, NIH 3T3 GFP and NIH 3T3 VEGFR2-GFP expressing
cells growing in 24-well plates were co-transfected with 400 ng of
pGL3 control or pGL3 VEGFR2 (-300/+1) or pGL3 VEGFR2 (-
116/+1) and 40 ng of the pCMV-bgal (Clontech Laboratories,
Inc., USA) using the Fugene 6 transfection reagent (Roche
Applied Science, USA). 24 h post-transfection, cells were harvest-
ed and luciferase activity was measured using Luciferase Assay
Reagent (Promega Corporation, USA). b-galoctosidase activity
was measured using Trophic Reagent (Applied Biosystems, USA).
Results were normalized by dividing the luciferase activity values
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luciferase activity.
Statistical Analysis
Data are represented as the mean 6 s.e.m., and statistical
analysis was performed with Student’s t test. A p value ,0.05 was
considered statistically significant.
Supporting Information
Figure S1 VEGFR2 and Sp1 relative gene expression is
decreased after VEGFR2 or Sp1 siRNA transfection. EC
were transfected with scrambled siRNA, VEGFR2 siRNA or Sp1
siRNA and 24 h later the VEGFR2 or Sp1 mRNA was quantified
by qRT-PCR. Data are mean 6 SD and represents the fold
change in VEGFR2 or Sp1 gene expression relative to the internal
calibrator (scrambled siRNA) in triplicates measurements and are
representative of three independent experiments.
(TIF)
Figure S2 Sp1 and VEGFR2 are present in the same
DNA/protein complexes. (A) Immunoprecipitation (IP) of
30 mg EC nuclear extract with anti-human VEGFR2 were
analysed by immunoblot. The immunodepleted extract (ID
VEGFR2) and Input were also included as control. (B) EMSA
analysis of the VEGFR2 promoter with IgG-immunodepleted (ID
Mouse IgG) (lane 3) or Sp1-immunodepleted (ID Sp1) extracts
were conducted. As a positive control EC nuclear extracts (lane 2,
5) were also evaluated. Four complexes (C1–C4) are indicated with
black arrows. Control lanes 1 and 4 contain only the radiolabeled
probe.
(TIF)
Figure S3 VEGFR2 binding to its own promoter is
independent of EGFR activation. ChIP assays of the
VEGFR2 proximal promoter were performed using EC cultured
in growing media and treated or not with 0.1 mM Iressa for 16 h.
Ethanol was used as vehicle in the control cells. ChIP values are
relative to control IgG background and normalized to an
intergenic region. Data are mean 6 s.e.m. of triplicates and
represents three independent experiments.
(TIF)
Table S1 VEGFR2-interacting proteins as identified by MS
analysis. Proteins listed according to their Mascot score.
(XLS)
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